Endo has licensed the exclusive rights from Bioniche to develop and market Urocidin in the US, with an option for global rights.

Urocidin is a patented formulation of Mycobacterial Cell Wall-DNA Complex developed by Bioniche. It is for the treatment of non-muscle-invasive bladder cancer that is currently undergoing Phase III clinical testing.

Under the agreement, Endo would pay Bioniche an upfront cash payment of $20m and the potential for up to $110m in additional payments, linked to the achievement of future clinical, regulatory and commercial milestones.

In addition, Bioniche will manufacture the product and receive a transfer price for supply.

Endo Pharmaceuticals president and CEO David Holveck said that company plans to expand its portfolio in bladder cancer treatment.

“In August 2009 Endo plans to launch Valstar for the treatment of bladder cancer. If successful in clinical development, Urocidin has the potential to extend and enhance our recent therapeutic expansion and strengthen the Valstar franchise,” Holveck said.